This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Discounting was not conducted since the costs were incurred during 2 years. The unit costs were reported separately from the quantities of resources. The health services included in the economic evaluation were in-hospital and followup services, such as percutaneous transluminal coronary angioplasty (PTCA) procedure, stent, intra-aortic balloon pumping, angiography, coronary artery bypass graft, repeat PTCA, coronary or intensive care unit stay, and ward stay. The follow-up visits included also echo, stress test, and radionuclide ejection faction. The resource use for follow-up was limited to cardiac hospitalisations, cardiac outpatient visits and diagnostic tests. The cost/resource boundary adopted was not explicitly reported, but appears to have been that of the hospital. The source of the cost data was not reported. The quantities of resources used were estimated through telephone interviews with the general practitioner of each patient, 24 months after the intervention. The patients also reported resource use, which was confirmed from hospital discharge summaries. The price year was not reported.
Statistical analysis of costs
Statistical analyses of the costs were conducted to test for the statistical significance of the results. Both parametric (Student's t-test) and non-parametric (Mann-Whitney U-test) tests were performed. It was assumed that the costs approached a bivariate distribution. Uncertainty was tested using confidence ellipses.
Indirect Costs
The indirect costs were not included in the analysis.
Currency
Dutch guilders (Dfl).
Sensitivity analysis
Sensitivity analyses were not performed.
Estimated benefits used in the economic analysis
See the 'Effectiveness Results' section.
Cost results
The per patient costs during initial hospitalisation were Dfl 21,484 in the stent group and Dfl 18,625 in the balloon group, (p=0.0001).
The per patient costs during follow-up were Dfl 9,939 in the stent group and Dfl 14,308 in the balloon group, (p=0.028).
The total per patient costs were Dfl 31,423 in the stent group and Dfl 32,933 in the balloon group, (p=0.83).
Synthesis of costs and benefits
Average and incremental cost-effectiveness ratios were calculated to combine the costs and benefits of the two angioplasty treatments.
The average cost per event-free survival was Dfl 37,408 in the stent group and Dfl 53,117 in the balloon group, (p<0.001).
The incremental cost-effectiveness ratio of stent angioplasty over balloon angioplasty was Dfl -6,297 (95% confidence interval: -18,828 -+16,390).
The statistical analyses based on confidence ellipses showed that the stent procedure was likely to be dominant (both NHS Economic Evaluation Database (NHS EED) Produced by the Centre for Reviews and Dissemination Copyright © 2020 University of York Page: 3 / 5 more effective and less costly) over balloon angioplasty. Stent angioplasty was more effective and more expensive under less likely conditions, but it was never less effective.
